John Heinzerling, MD
The FDA is currently reviewing a supplemental biologics license application for the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with stage III, unresectable non–small cell lung cancer (NSCLC), based on positive progression-free survival (PFS) results from the phase III PACIFIC trial.
on Advanced Non–Small Cell Lung Cancer, Heinzerling, a radiation oncologist in the Department of Radiation Oncology at the Levine Cancer Institute, discussed the impact of durvalumab and other developments in the treatment of patients with stage III NSCLC.
OncLive: Can you provide an overview of your presentation on immunotherapy for patients with stage III locally advanced lung cancer?
: First, I discussed where we currently are with combination chemotherapy and radiation therapy for stage III disease. I reviewed the progress that has been made in the last 15 years.
... to read the full story